How AI can help target protein that contributes to pancreatic cancer, Pg13

Key Highlights:

• Mayo Clinic and Bengaluru-based Sravathi AI Technology co-developed a cancer treatment targeting the GIPC1 protein.
• The treatment aims to inhibit GIPC1, which contributes to the growth of various cancers, including pancreatic cancer.
• The findings of this research were published in the scientific journal Cell Reports.
• The collaboration utilized advanced computational modeling and artificial intelligence to identify a specific small molecule inhibitor.

AI Cancer Drug.jpg

Detailed Insights:

• GIPC1 does not directly cause cancer but facilitates cancer cell growth and invasion when its expression or signaling is problematic.
• Pancreatic Ductal Adenocarcinoma (PDAC), an aggressive form of pancreatic cancer, has a five-year survival rate under 13.3% due to late diagnosis and therapeutic resistance.
• GIPC1 was previously considered "undruggable" because its PDZ domain interacts broadly with multiple proteins, making conventional targeting difficult.
• Sravathi AI used Generative AI to design initial molecules and Predictive AI to assess properties like toxicity and absorption.
• The drug discovery process involved narrowing down 40,000 molecules to a final candidate using molecular modeling and quantum chemistry.
• The initial research phase took approximately five months, with potential human use estimated in about three years following animal trials.

Scientific/Technical Concepts Involved:

• GIPC1: A protein whose problematic expression or signaling can contribute to cancer cell growth and chemotherapy resistance.
• Pancreatic Ductal Adenocarcinoma (PDAC): The most common and aggressive type of exocrine pancreatic cancer with a very low survival rate.
• PDZ domain: A protein interaction domain found in signaling proteins, crucial for GIPC1's function and a challenge for drug targeting.
• Small molecule inhibitor: A type of drug that blocks the activity of a specific protein, identified here to target the PDZ domain of GIPC1.
• Generative AI: Artificial intelligence used to design novel molecules with specific desired properties for drug discovery.
• Predictive AI: Artificial intelligence employed to forecast and assess various characteristics of drug candidates, such as toxicity and absorption.